Trials / Withdrawn
WithdrawnNCT02557854
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Theodore Laetsch · Academic / Other
- Sex
- All
- Age
- 1 Year – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Doxil (liposomal doxorubicin) given prior to MR-HIFU Hyperthermia is safe for the treatment of pediatric and young adult patients with recurrent and refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxorubicin HCl liposomal injection | 50mg IV every 4 weeks |
| DEVICE | Philips Sonalleve MR-HIFU Hyperthermia | Hyperthermia to 42C for 30 minutes every 4 weeks |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2019-03-16
- Completion
- 2019-03-16
- First posted
- 2015-09-23
- Last updated
- 2019-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02557854. Inclusion in this directory is not an endorsement.